"Becton Dickinson is framed as an attractive defensive compounder trading at a depressed valuation despite holding a dominant global market position in essential medical consumables."

"Omnicell was framed as a compelling small-cap business positioned for significant revenue acceleration driven by an upcoming ten-year hardware refresh cycle and long-term sole-source contracts."